Prior to Lung Transplant: The following questions refer to the pre-transplant period.
Does your center employ pre-transplant, pharmacologic anti-fungal prophylaxis?
○ Yes
○ No
○ Unsure
What prompts pharmacologic anti-fungal prophylaxis prior to lung transplantation (Select all that apply)?
□ Airway colonization with Aspergillus sp.
□ Airway colonization with molds other than Aspergillus sp.
□ Airway colonization with non-Candida yeast
□ Airway colonization with Candida sp.
□ Diagnosis of Cystic Fibrosis
□ Patien’s occupation
□ Patien’s geographic location
□ Presence of bronchiectasis without diagnosis of Cystic Fibrosis
□ Our center uses universal pre-transplant anti-fungal prophylaxis
□ Other
Please describe “Other”
What is the goal of pre-transplant anti-fungal prophylaxis (Select all that apply)?
□ Prevention of post-transplantation tracheobronchitis
□ Prevention of post-transplantation invasive fungal infection
□ Other
Please describe “Other”
What anti-fungal agent(s) is preferred by your center for pre-transplant anti-fungal prophylaxis? (You may select up to 1 topical and 1 systemic agent)
Topical agents:
○ Aerosolized amphotericin B
○ Other
○ No topical agent is used
Please describe “Other”
Systemic agents:
○ Amphotericin
○ Anidulafungin
○ Caspofungin
○ Fluconazole
○ Micafungin
○ Isavuconazole
○ Itraconazole
○ Posaconazole
○ Voriconazole
○ Other
○ No systemic agent is used
Please describe “Other”
What is the average duration of pre-transplant topical (i.e. nebulized or aerosolized) anti-fungal prophylaxis?
○ Less than 3 months
○ 3 to 6 months
○ Greater than 6 months but less than 12 months
○ 12 months or greater
○ Other
Please describe “Other”
What is the average duration of pre-transplant systemic anti-fungal prophylaxis?
○ Less than 3 months
○ 3 to 6 months
○ Greater than 6 months but less than 12 months
○ 12 months or greater
○ Other
Please describe “Other”
What is the dosing method for your center’s preferred systemic anti-fungal?
○ Standard uniform dosing regardless of serum anti-fungal levels
○ Dosed to a serum “detectable” anti-fungal level
○ Dosed to a specific target serum anti-fungal level
○ Other
Please describe “Other”
Do patients listed for lung transplant receive inhaled amphotericin prior to lung transplantation for prophylaxis?
○ All patients receive inhaled amphotericin prior to lung transplantation
○ No patients receive inhaled amphotericin prior to lung transplantation
○ Some patients receive inhaled amphotericin prior to lung transplantation
Which patients receive inhaled amphotericin prior to lung transplantation (select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with history of invasive Aspergillus sp. infection
□ Patients with history of invasive mold (other than Aspergillus sp.) infection
□ Patients with history of non-Candida yeast infection
□ Patients with history Candida sp. infection
□ Other
Please describe “Other”
Do patients listed for lung transplant receive systemic triazole therapy prior to lung transplantation for prophylaxis? Triazole therapy includes: fluconazole, voriconazole, itraconazole, posaconazole, isavuconazole.
○ All patients receive systemic triazole prior to lung transplantation
○ No patients receive systemic triazole prior to lung transplantation
○ Some patients receive triazole therapy prior to lung transplantation
Which patients receive triazole therapy prior to lung transplantation (select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with history of invasive Aspergillus sp. Infection
□ Patients with history of invasive mold (other than Aspergillus sp.) infection
□ Patients with history of non-Candida yeast infection
□ Patients with history of Candida sp. infection
□ Other
Please describe “Other”
Do patients listed for lung transplant receive systemic echinocandin therapy prior to lung transplantation for prophylaxis? Echinocandin therapy includes: caspofungin, micafungin, anidulafungin.
○ All patients receive systemic echinocandin prior to lung transplantation
○ No patients receive systemic echinocandin prior to lung transplantation
○ Some patients receive echinocandin therapy prior to lung transplantation
Which patients receive echinocandin therapy prior to lung transplantation (select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with history of invasive Aspergillus sp. infection
□ Patients with history of invasive mold (other than Aspergillus sp.) infection
□ Patients with history of non-Candida yeast infection
□ Patients with history of Candida sp. infection
□ Other
Please describe “Other”
Do patients listed for lung transplant receive systemic amphotericin therapy prior to lung transplantation for prophylaxis?
○ All patients receive systemic amphotericin prior to lung transplantation
○ No patients receive systemic amphotericin prior to lung transplantation
○ Some patients receive systemic amphotericin therapy prior to lung transplantation
Which patients receive systemic amphotericin therapy prior to lung transplantation (select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with Aspergillus sp. Airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with history of invasive Aspergillus sp. Infection
□ Patients with history of invasive mold (other than Aspergillus sp.) infection
□ Patients with history of non-Candida yeast infection
□ Patients with history of Candida sp. infection
□ Other
Please describe “Other”